Genomics service provider Expression Analysis said this week that it has begun offering sequencing services on Pacific Biosciences' single-molecule sequencing platform.
The company, based in Durham, NC, said it is the first commercial provider offering services on the PacBio RS system in the US.
According to EA, first applications for the PacBio RS include de novo and hybrid genome assemblies, pathogen identification, and targeted resequencing. The company said it has already lined up several sequencing projects, including viral and bacterial sequencing studies with a large undisclosed pharmaceutical client and with academic institutions and plant and animal studies with government and commercial organizations.
PacBio is recommending EA as its North American service provider for the pharmaceutical market. "Given their deep expertise working with new and emerging genomic technologies and the world's leading pharmaceutical companies, EA is a natural fit to be our recommended commercial partner for providing sequencing services to the drug discovery and development market," said Pat Brooks, vice president of sales at PacBio, in a statement.